GLP-1 for diabetes vs weight loss: same drug, different rules
Ozempic and Wegovy are the same molecule. Mounjaro and Zepbound are the same molecule. The differences are in dose, indication, insurance coverage, and what your prescription actually says.
This trips up almost everyone the first time they look at GLP-1s seriously: Ozempic and Wegovy are the same drug (semaglutide). Mounjaro and Zepbound are the same drug (tirzepatide). They're sold under different names with different doses and different indications.
The split matters because insurance, regulatory framing, and program eligibility all hinge on which name appears on the prescription.
The basic mapping
| Active drug | Diabetes brand | Weight-loss brand | Maker |
|---|---|---|---|
| Semaglutide injectable | Ozempic | Wegovy | Novo Nordisk |
| Semaglutide oral pill | Rybelsus | (Wegovy oral, 2025+) | Novo Nordisk |
| Tirzepatide | Mounjaro | Zepbound | Eli Lilly |
| Liraglutide | Victoza | Saxenda | Novo Nordisk |
| Dulaglutide | Trulicity | (none) | Eli Lilly |
The differences that matter
Dose ceilings. Wegovy goes up to 2.4mg/week of semaglutide; Ozempic tops out at 2.0mg. Zepbound and Mounjaro share the same 2.5-15mg dose range. For weight loss, the higher Wegovy dose is meaningful — some patients need it.
Insurance formulary. Most US commercial plans cover the diabetes brand for diabetes patients (with prior auth) and the weight-loss brand for obesity patients (with prior auth, BMI requirements). Medicare and many Medicaid plans cover the diabetes brands but not the weight-loss brands. This is a meaningful gap for older or lower-income patients.
Off-label prescribing. Many telehealth programs prescribe Ozempic or Mounjaro off-label for weight loss. This is legal and common, but creates two complications:
- Insurance may deny because the diagnosis on file is weight loss, not diabetes
- Some pharmacies will not fill a Mounjaro prescription for a non-diabetic patient even if the prescription is valid
Manufacturer savings cards. Both Novo and Lilly offer commercial-only patient assistance cards that reduce branded GLP-1 cost. The cards are tied to the brand name; you cannot use a Wegovy card for an Ozempic prescription, even though it's the same drug.
Compounded versions. Compounded semaglutide and tirzepatide are not branded as either diabetes or weight-loss products. They are simply "compounded semaglutide" prescribed for whatever indication the prescriber documents. This regulatory ambiguity has been a feature for cash-pay weight-loss programs and a target for branded manufacturers' lawsuits.
What this means for program choice
If you have diabetes:
- Insurance-coverage paths through Ozempic, Mounjaro, or Trulicity are usually the cheapest option. Programs like 9amHealth, Knownwell, and Form Health handle this well.
- You typically get the diabetes brand at diabetes-tier copay (often $25-50/mo).
- If you also have obesity-grade BMI, you may qualify for both indications, which expands prescription flexibility.
If you don't have diabetes but do have obesity:
- Wegovy or Zepbound is your indicated drug.
- Insurance coverage requires obesity-grade BMI (≥30, or ≥27 with comorbidity) plus prior auth.
- Cash-pay branded options: NovoCare for Wegovy ($149-$299/mo), LillyDirect for Zepbound vials ($299-$449/mo).
- Compounded paths through programs like Mochi and Henry Meds remain cheapest at $178-$297/mo all-in.
If you're prediabetic (HbA1c 5.7-6.4%):
- You're in the gray zone. Some plans cover Wegovy/Zepbound for prediabetes + obesity; many do not. Check formulary.
- 9amHealth's cardiometabolic model is purpose-built for this scenario and worth considering.
Why is the same drug priced differently?
The cynical answer: because the manufacturer can. Novo Nordisk launched Wegovy at a higher price than Ozempic primarily because the obesity indication has lower insurance penetration and higher cash-pay willingness. The clinical molecule, the manufacturing process, and the safety profile are identical.
Generic semaglutide arrival (late 2026 to early 2027) will collapse this brand-based pricing distinction over time. Generic semaglutide will likely be priced as a single product with both diabetes and weight-loss indications.
The simple decision rule
Ask your program which specific brand they're prescribing and whether your insurance covers it for your diagnosis. Not "do you take insurance?" but "for my BMI of 32 and no diabetes, will you prescribe Wegovy through my BlueCross plan, and what's the realistic copay?" Programs that can answer this in concrete terms (Form Health, 9amHealth, PlushCare) will save you weeks of insurance back-and-forth. Programs that hand-wave through it will not.